Lupin eyes 15% share for Yasmin copy amid expectations of market shake up
This article was originally published in Scrip
Executive Summary
Lupin’s Yasmin (drospirenone and ethinyl estradiol tablets) copy could potentially shake things up in the US market, some analysts suggest, referring to the Indian firm’s high vertical integration and price advantage.